bioRxivImmunology
Design and Characterization of Lipid Nanocarriers for Oral Delivery of Immunotherapeutic Peptides
X. Calderon Colon, Y. Zhang, O. Tiburzi, J. Wang, G. Raimondi, J. Patrone
Abstract
The use of therapeutic proteins and peptides is of great interest for the treatment of many diseases, and advances in nanotechnology offer a path toward their stable delivery via preferred routes of administration. In this study, we sought to design and formulate a nanostructured lipid carrier (NLC) containing a nominal antigen (insulin peptide) for oral delivery. We utilized the design of experiments (DOE) statistical method to determine the dependencies of formulation variables on physicochemical particle characteristics including particle size, polydispersity (PDI), melting point, and latent heat of melting. The particles were determined to be non-toxic in vitro, readily taken up by primary immune cells, and found to accumulate in regional lymph nodes following oral administration. We believe that this platform technology could be broadly useful for the treatment of autoimmune diseases by supporting the development of oral delivery-based antigen specific immunotherapies. Highlights3-5 bullets, 85 char or less O_LIA Design of Experiments method led the formulation of biocompatible nanoparticles C_LIO_LINLC accumulate into gut-draining lymphatic tissues following oral administration C_LIO_LINLC protect their antigen cargo and promote its presentation C_LIO_LINLC formulation is well-suited for oral delivery of immunomodulatory agents C_LI Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=107 SRC="FIGDIR/small/478027v1_ufig1.gif" ALT="Figure 1"> View larger version (37K): org.highwire.dtl.DTLVardef@1d18054org.highwire.dtl.DTLVardef@14038ddorg.highwire.dtl.DTLVardef@1555abdorg.highwire.dtl.DTLVardef@b83a42_HPS_FORMAT_FIGEXP M_FIG The development of nanostructured lipid carriers containing a nominal antigen (insulin peptide) for oral delivery consists on (1) nanoparticle formulation using a statistical method, (2) in-vitro studies to assess cellular toxicity and uptake and T cell activation, and (3) in-vivo studies to assess bio-distribution. C_FIG
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Disc-Toroid Hybrid Lipid Nanoparticles for Efficient Drug Encapsulation and Subcutaneous Delivery
Zanelle van Niekerk, Rima Nuwayhid, … Albena Lederer·SmallPeer-reviewed·Mar 12, 2026
- LipiGo: A Versatile DNA-Lipid Nanoparticle Hybrid for Precision Drug Delivery
Karoline Kadletz, Ceren Kımna, … Ali Ertürk·bioRxiv·Sep 15, 2025
- Tuning the immunostimulation properties of cationic lipid nanocarriers for nucleic acid delivery
A. K. Dey, A. Nougarede, … P. N. Marche·bioRxiv·Jun 16, 2021
- Engineering nanoparticle surface chemistry for antigen-presenting cell targeting improves specificity and safety of TLR3 agonist cancer immunotherapy
Victoria F. Gomerdinger, Cassandra Parada, … Paula Therese Hammond·bioRxiv·Jun 25, 2026
- Physicochemical characterization, toxicity and in vivo biodistribution studies of a discoidal, lipid-based drug delivery vehicle: Lipodisq nanoparticles containing doxorubicin
M. L. Torgersen, P. J. Judge, … K. Sandvig·bioRxiv·Jun 18, 2020
- Smart-design of universally decorated nano-particles for drug delivery applications driven by active transport
G. Halbi, I. Fayer, … A. Bernheim-Groswasser·bioRxiv·Jun 16, 2022